Text Size

Platelet Hyperreactivity Project (PHP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by University Hospital, Geneva.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00976196
First received: September 11, 2009
Last updated: September 14, 2009
Last verified: September 2009
History of Changes
  Purpose

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.


Condition
Platelet Reactivity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients

Resource links provided by NLM:

Drug Information available for: Aspirin
U.S. FDA Resources

Further study details as provided by University Hospital, Geneva:

Biospecimen Retention:   Samples With DNA

Plasma Serum Platelets


Estimated Enrollment: 100
Study Start Date: January 2009
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Detailed Description:

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.

Main objective:

  • to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary objectives:

  • to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin
  • to determine genetic polymorphisms associated with platelet hyperreactivity
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Symptomatic atherothrombotic patients treated with aspirin.

Criteria

Inclusion Criteria:

  • Documented symptomatic ischemic atherothrombotic disease treated by aspirin.

Exclusion Criteria:

  • Known platelet disorder
  • Chronic treatment by antiplatelet drugs other than aspirin
  • Chronic anticoagulant treatment
  • Chronic non steroidal anti-inflammatory drug treatment
  • Active cancer
  • Treatment with serotonin reuptake inhibitors
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00976196

Contacts
Contact: Pierre Fontana, MD, PhD +41223795938 pierre.fontana@unige.ch

Locations
Switzerland
University Hospital Geneva Recruiting
Geneva, Switzerland, 1205
Contact: Pierre Fontana, MD, PhD         pierre.fontana@unige.ch    
Principal Investigator: Pierre Fontana, MD, PhD            
Sub-Investigator: Jean-Charles Sanchez, PhD            
Sponsors and Collaborators
University Hospital, Geneva
Investigators
Principal Investigator: Pierre Fontana, MD, PhD University of Geneva
  More Information

No publications provided

Responsible Party: P. Fontana, University hospital, Geneva
ClinicalTrials.gov Identifier: NCT00976196     History of Changes
Other Study ID Numbers: 08-104
Study First Received: September 11, 2009
Last Updated: September 14, 2009
Health Authority: Switzerland: Federal Office of Public Health

Keywords provided by University Hospital, Geneva:
Aspirin
Blood platelets
proteomics
Platelet reactivity

ClinicalTrials.gov processed this record on May 21, 2013